SLC5A2 and type 2 diabetes mellitus: Empagliflozin is an SGLT2 inhibitor approved for the treatment of T2DM, which can reduce the risk of cardiovascular death in patients with T2DM and cardiovascular disease (JARDIANCE prescribing information, 2020).